We are live on ! Find out more
PALI icon

Palisade Bio

86 hedge funds and large institutions have $319M invested in Palisade Bio in 2025 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

310,512% more capital invested

Capital invested by funds: $103K → $319M (+$319M)

7,400% more first-time investments, than exits

New positions opened: 75 | Existing positions closed: 1

617% more funds holding

Funds holding: 1286 (+74)

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

89.88% more ownership

Funds ownership: 1.31%91.19% (+90%)

Holders
86
Holders Change
+74
Holders Change %
+616.67%
% of All Funds
0%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0%
New
75
Increased
7
Reduced
1
Closed
1
Calls
Puts
Net Calls
Net Calls Change

PALI Hedge Fund Activity: Q4 2025 in Review

86 institutional investors reported a position in Palisade Bio (PALI) for Q4 2025, worth a combined $319M — up 310,512% from $103K a quarter earlier.

Buyers outnumbered sellers: 75 funds opened new PALI positions and 1 closed out — a net gain of 74 holders — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $23.2M. The largest seller was Two Sigma Securities, exiting entirely with an estimated $25.3K sold.

  • 86 institutional investors held Palisade Bio (PALI) as of Q4 2025, up from 12 in Q3 2025.
  • Funds reported $319M of Palisade Bio stock for Q4 2025, up 310,512% quarter-over-quarter.
  • 75 funds opened new Palisade Bio positions in Q4 2025 and 1 closed out, a net change of +74 holders.
  • The largest Palisade Bio buyer in Q4 2025 was Perceptive Advisors, an estimated $23.2M added.
  • The largest Palisade Bio seller in Q4 2025 was Two Sigma Securities, an estimated $25.3K sold.

Based on aggregated 13F filings for Q4 2025.